http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-063259-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4965 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1676 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32 |
| filingDate | 2007-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-063259-A1 |
| titleOfInvention | SOLID FORMS OF PHARMACEUTICAL DOSAGE THAT INCLUDES MICROINCLUDED COMPOUNDS IN IONIC POLYMERS INSOLUBLE IN WATER |
| abstract | Solid pharmaceutical dosage forms for oral administration comprising a therapeutically effective amount of an unstable crystalline form or an amorphous form of a therapeutically effective compound microincluded in a water insoluble ionic polymer. The therapeutically effective compounds, which have a tendency to melify, are microincluded in a water-insoluble ionic polymer matrix to provide a dosage form with a rapid, reproducible and complete dissolution profile. These new solid pharmaceutical dosage forms are useful for the treatment or control of a series of diseases. Claim 2: The dosage form according to claim 1, wherein the therapeutically effective compound is a glucokinase activating compound. Claim 4: The dosage form according to claim 3, wherein the glucokinase activating compound is 2 (R) - (3-chloro-4-methanesulfonyl-phenyl) -3-cyclo-pentyl-N- ( 5- (1 (S), 2-dihydroxyethyl) -pyrazin-2-yl] -propionamide Claim 11: The dosage form according to claim 10, wherein the water insoluble ionic polymer is an acid copolymer methacrylic and ethyl acrylate Claim 15: The dosage form according to claims 1 to 13 for the treatment of type 2 diabetes. Claim 16: A method for the preparation of a solid pharmaceutical dosage form for oral administration comprising the microinclusion of a therapeutically effective amount of an unstable crystalline form or an amorphous form in a water insoluble ionic polymer, in which the proportion of the therapeutically effective compound and the ionic polymer carrier is 5: 1 to 1: 5, respectively . |
| priorityDate | 2006-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 166.